Literature DB >> 10096568

De-N-acetyl-gangliosides in humans: unusual subcellular distribution of a novel tumor antigen.

R Chammas1, J L Sonnenburg, N E Watson, T Tai, M G Farquhar, N M Varki, A Varki.   

Abstract

The disialoganglioside GD3 is a major antigen in human melanomas that can undergo 9-O-acetylation of the outer sialic acid (giving 9-OAc-GD3). Monoclonal antibody SGR37 detects a different modification of the GD3, de-N-acetylation of the 5-N-acetyl group (giving de-N-Ac-GD3). We found that conventional immunohistochemistry of the SGR37 antigen is limited by a reduction in reactivity upon fixation with aldehydes (which presumably react with the free amino group) or with organic reagents (which can extract glycolipids). We optimized conditions for detection of this antigen in unfixed frozen tissue sections and studied its distribution in human tissues and tumors. It is expressed at low levels in a few blood vessels, infiltrating mononuclear cells in the skin and colon, and at moderate levels in skin melanocytes. In contrast, the antigen accumulates at high levels in many melanomas and in some lymphomas but not in carcinomas. In positive melanomas, expression is sometimes more intense and widespread than that of GD3. Both 9-O-acetylation and de-N-acetylation of GD3 seem to occur after its initial biosynthesis. Isotype-matched antibodies against GD3, 9-O-acetyl-GD3 and de-N-acetyl-GD3 were used to compare their subcellular localization and trafficking. 9-O-acetyl-GD3 colocalizes with GD3 predominantly on the cell surface and partly in lysosomal compartments. In contrast, de-N-acetyl-GD3 has a diffuse intracellular location. Adsorptive endocytosis of antibodies indicates that whereas GD3 remains predominantly on the cell surface, de-N-acetyl-GD3 is efficiently internalized into a compartment that is distinct from lysosomes. Rounding up of melanoma cells occurring during growth in culture is associated with relocation of the internal pool of de-N-acetyl-GD3 to the cell surface. Thus, a minor modification of the polar head group of a tumor-associated glycosphingolipid can markedly affect the subcellular localization and trafficking of the whole molecule. The high levels of the SGR37 antigen in melanomas and lymphomas, its selective endocytosis from the cell surface, and its relocation to the cell surface of rounded up cells suggest potential uses in diagnostic or therapeutic approaches to these diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10096568

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Vaccines containing de-N-acetyl sialic acid elicit antibodies protective against neisseria meningitidis groups B and C.

Authors:  Gregory R Moe; Tamara S Bhandari; Becca A Flitter
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

2.  Combinatorial Design of a Sialic Acid-Imprinted Binding Site.

Authors:  Liliia Mavliutova; Elena Verduci; Sudhirkumar A Shinde; Börje Sellergren
Journal:  ACS Omega       Date:  2021-04-29

3.  An antibody to de-N-acetyl sialic acid containing-polysialic acid identifies an intracellular antigen and induces apoptosis in human cancer cell lines.

Authors:  Lindsay M Steirer; Gregory R Moe
Journal:  PLoS One       Date:  2011-11-09       Impact factor: 3.240

4.  Small changes huge impact: the role of protein posttranslational modifications in cellular homeostasis and disease.

Authors:  Tejaswita M Karve; Amrita K Cheema
Journal:  J Amino Acids       Date:  2011-07-21

5.  O-acetylation of GD3: an enigmatic modification regulating apoptosis?

Authors:  Helen Y Chen; Ajit Varki
Journal:  J Exp Med       Date:  2002-12-16       Impact factor: 14.307

Review 6.  Glycosylation of glycolipids in cancer: basis for development of novel therapeutic approaches.

Authors:  Jose L Daniotti; Aldo A Vilcaes; Vanina Torres Demichelis; Fernando M Ruggiero; Macarena Rodriguez-Walker
Journal:  Front Oncol       Date:  2013-12-19       Impact factor: 6.244

Review 7.  Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy.

Authors:  Julien Fleurence; Sophie Fougeray; Meriem Bahri; Denis Cochonneau; Béatrice Clémenceau; François Paris; Andras Heczey; Stéphane Birklé
Journal:  J Immunol Res       Date:  2017-01-05       Impact factor: 4.818

8.  Challenging tumour immunological techniques that help to track cancer stem cells in malignant melanomas and other solid tumours.

Authors:  Beatrix Kotlan; Vanda Plotar; Klara Eles; Szabolcs Horvath; Timea Balatoni; Orsolya Csuka; Mihaly Újhelyi; Ákos Sávolt; Andras Szollar; Istvan Vamosi-Nagy; Laszlo Toth; Emil Farkas; Jozsef Toth; Miklos Kasler; Gabriella Liszkay
Journal:  Contemp Oncol (Pozn)       Date:  2018-03-05

9.  Tumor-Associated Disialylated Glycosphingolipid Antigen-Revealing Antibodies Found in Melanoma Patients' Immunoglobulin Repertoire Suggest a Two-Direction Regulation Mechanism Between Immune B Cells and the Tumor.

Authors:  Beatrix Kotlan; Szabolcs Horvath; Klara Eles; Vanda K Plotar; Gyorgy Naszados; Katalin Czirbesz; Miri Blank; Emil Farkas; Laszlo Toth; Jozsef Tovari; Andras Szekacs; Yehuda Shoenfeld; Maria Godeny; Miklos Kasler; Gabriella Liszkay
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

10.  Localisation and distribution of O-acetylated N-acetylneuraminic acids, the endogenous substrates of the hemagglutinin-esterases of murine coronaviruses, in mouse tissue.

Authors:  Andreas Rinninger; Colette Richet; Alexandre Pons; Guido Kohla; Roland Schauer; Hans-Christian Bauer; Jean-Pierre Zanetta; Reinhard Vlasak
Journal:  Glycoconj J       Date:  2006-02       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.